Skip to main content
. Author manuscript; available in PMC: 2024 Nov 14.
Published in final edited form as: Immunity. 2023 Nov 14;56(11):2555–2569.e5. doi: 10.1016/j.immuni.2023.10.010

Figure 6. TSC1-deficient TAMs display enhanced efferocytosis and mitochondrial activities.

Figure 6.

(A) Representative flow cytometric analysis (left) and quantification (right) of CD107a (LAMP1) expression in TAMs from Tsc1fl/flPyMT (n = 7) and CD11cCreTsc1fl/flPyMT (n = 6) mice.

(B) Representative flow cytometric analysis (left) and quantification (right) of CellTrace Violet (CTV)-labelled apoptotic cell engulfment in TAMs from Tsc1fl/flPyMT (n = 3) and CD11cCreTsc1fl/flPyMT (n = 3) mice.

(C) Representative flow cytometric analysis (left) and quantification (right) of mitochondrial mass (MitoTracker Green FM, Y axis) and mitochondrial potential (MitoTracker Red CMXRos, X axis) in TAMs from Tsc1fl/flPyMT (n = 7) and CD11cCreTsc1fl/flPyMT (n = 7) mice.

(D) Representative flow cytometric analysis (left) and quantification (right) of mitochondrial ROS (MitoSOX Red) production in TAMs from Tsc1fl/flPyMT (n = 9) and CD11cCreTsc1fl/flPyMT (n = 9) mice.

(E) Representative analysis (left) and quantification (right) of extracellular acidification rate (ECAR) of TAMs from Tsc1fl/flPyMT and CD11cCreTsc1fl/flPyMT mice. Sequential chemical treatments are indicated (Oligo, oligomycin; 2-DG, 2-Deoxy-D-glucose).

(F) Representative analysis (left) and quantification (right) of oxygen consumption rate (OCR) of TAMs from Tsc1fl/flPyMT and CD11cCreTsc1fl/flPyMT mice. Sequential chemical treatments are indicated (Oligo, oligomycin; FCCP, trifluoromethoxy carbonylcyanide phenylhydrazone; Ant, antimycin A; Rot, rotenone).

All data are shown as mean ± SEM, unpaired t-test, two-tailed, *: p < 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001, and n.s. = not significant.

See also Figure S6.